• +1-646-491-9876
    • +91-20-67278686

    Search

    Gallbladder Cancer - Pipeline Review, H2 2016

    Gallbladder Cancer - Pipeline Review, H2 2016

    • Report Code ID: RW0001492631
    • Category Pharmaceuticals
    • No. of Pages 74
    • Publication Month Nov-16
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gallbladder Cancer - Pipeline Review, H2 2016, provides an overview of the Gallbladder Cancer (Oncology) pipeline landscape.

    Gallbladder cancer is a cancer that starts in the gallbladder. Symptoms include abdominal pain, nausea and/or vomiting, jaundice, loss of appetite, fever, itchy skin, dark urine and weight loss. Risk factors include overweight, age, family history, gallstones, gender and choledochal cysts. Treatment includes surgery, chemotherapy and radiation therapy.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Gallbladder Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Gallbladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Gallbladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gallbladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Gallbladder Cancer.

    Gallbladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Gallbladder Cancer (Oncology).
    - The pipeline guide reviews pipeline therapeutics for Gallbladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Gallbladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Gallbladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Gallbladder Cancer (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Gallbladder Cancer (Oncology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Gallbladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Gallbladder Cancer Overview 6
    Therapeutics Development 7
    Pipeline Products for Gallbladder Cancer - Overview 7
    Pipeline Products for Gallbladder Cancer - Comparative Analysis 8
    Gallbladder Cancer - Therapeutics under Development by Companies 9
    Gallbladder Cancer - Therapeutics under Investigation by Universities/Institutes 10
    Gallbladder Cancer - Pipeline Products Glance 11
    Clinical Stage Products 11
    Gallbladder Cancer - Products under Development by Companies 12
    Gallbladder Cancer - Products under Investigation by Universities/Institutes 13
    Gallbladder Cancer - Companies Involved in Therapeutics Development 14
    4SC AG 14
    harma Inc 14
    BeiGene Ltd 16
    Eli Lilly and Company 17
    Novartis AG 18
    VasGene Therapeutics Inc 19
    Gallbladder Cancer - Therapeutics Assessment 20
    Assessment by Monotherapy Products 20
    Assessment by Target 21
    Assessment by Mechanism of Action 23
    Assessment by Route of Administration 25
    Assessment by Molecule Type 27
    Drug Profiles 29
    BGBA-317 - Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    binimetinib - Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    Cellular Immunotherapy to Target CD-3 and HER-2 for Oncology - Drug Profile 38
    Product Description 38
    Mechanism Of Action 38
    R&D Progress 38
    copanlisib hydrochloride - Drug Profile 39
    Product Description 39
    Mechanism Of Action 39
    R&D Progress 39
    DKN-01 - Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    merestinib - Drug Profile 45
    Product Description 45
    Mechanism Of Action 45
    R&D Progress 45
    ramucirumab - Drug Profile 47
    Product Description 47
    Mechanism Of Action 47
    R&D Progress 47
    resminostat - Drug Profile 56
    Product Description 56
    Mechanism Of Action 56
    R&D Progress 56
    trametinib dimethyl sulfoxide - Drug Profile 65
    Product Description 65
    Mechanism Of Action 65
    R&D Progress 65
    Vas-01 - Drug Profile 69
    Product Description 69
    Mechanism Of Action 69
    R&D Progress 69
    Gallbladder Cancer - Dormant Projects 71
    Gallbladder Cancer - Discontinued Products 72
    Appendix 73
    Methodology 73
    Coverage 73
    Secondary Research 73
    Primary Research 73
    Expert Panel Validation 73
    Contact Us 73
    Disclaimer 74

    List of Tables

    Number of Products under Development for Gallbladder Cancer, H2 2016 7
    Number of Products under Development for Gallbladder Cancer - Comparative Analysis, H2 2016 8
    Number of Products under Development by Companies, H2 2016 9
    Number of Products under Investigation by Universities/Institutes, H2 2016 10
    Comparative Analysis by Clinical Stage Development, H2 2016 11
    Products under Development by Companies, H2 2016 12
    Products under Investigation by Universities/Institutes, H2 2016 13
    Gallbladder Cancer - Pipeline by 4SC AG, H2 2016 14
    Gallbladder Cancer - Pipeline by Array BioPharma Inc, H2 2016 15
    Gallbladder Cancer - Pipeline by Bayer AG, H2 2016 15
    Gallbladder Cancer - Pipeline by BeiGene Ltd, H2 2016 16
    Gallbladder Cancer - Pipeline by Eli Lilly and Company, H2 2016 17
    Gallbladder Cancer - Pipeline by Novartis AG, H2 2016 18
    Gallbladder Cancer - Pipeline by VasGene Therapeutics Inc, H2 2016 19
    Assessment by Monotherapy Products, H2 2016 20
    Number of Products by Stage and Target, H2 2016 22
    Number of Products by Stage and Mechanism of Action, H2 2016 24
    Number of Products by Stage and Route of Administration, H2 2016 26
    Number of Products by Stage and Molecule Type, H2 2016 28
    Gallbladder Cancer - Dormant Projects, H2 2016 71
    Gallbladder Cancer - Discontinued Products, H2 2016 72

    List of Figures

    Number of Products under Development for Gallbladder Cancer, H2 2016 7
    Number of Products under Development for Gallbladder Cancer - Comparative Analysis, H2 2016 8
    Number of Products under Development by Companies, H2 2016 9
    Comparative Analysis by Clinical Stage Development, H2 2016 11
    Assessment by Monotherapy Products, H2 2016 20
    Number of Products by Top 10 Targets, H2 2016 21
    Number of Products by Stage and Top 10 Targets, H2 2016 21
    Number of Products by Top 10 Mechanism of Actions, H2 2016 23
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 23
    Number of Products by Routes of Administration, H2 2016 25
    Number of Products by Stage and Routes of Administration, H2 2016 25
    Number of Products by Molecule Types, H2 2016 27
    Number of Products by Stage and Molecule Types, H2 2016 27
    4SC AG
    harma Inc
    BeiGene Ltd
    Eli Lilly and Company
    Novartis AG
    VasGene Therapeutics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//gallbladder-cancer-pipeline-review-h2-2016&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//gallbladder-cancer-pipeline-review-h2-2016&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//gallbladder-cancer-pipeline-review-h2-2016&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments